All In Biotech

Drug Trial Radar · NCT07429474

Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema

Phase I Clinical Trial to Evaluate Safety by Determining Immunogenicity Following Unilateral Intravitreal Administration of PRO-169 in Patients With Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Dec 15, 2026

Study completion Dec 15, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.

Conditions

  • Immunogenicity
  • Anti-drug Antibodies (ADAs)

Interventions

  • PRO-169Biological

    Bevacizumab 1.25 mg / 0.05mL for intravitreal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with positive serum ADAs for bevacizumab.Time frame: Day 0 (Selection), day 30± 5 (visit 5, V5), day 60 ± 5 (visit 6, V6) and day 90± 5 (final visit, FV)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asociación para Evitar la Ceguera en México I.A.P

    Coyoacán, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.